GlassScriptPhysician profile
Britny Rockelman
NPI 1679336069
$1,683.43
in general payments reported to CMS, 2019-2025
22 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $558 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,683.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $268.53 | 2024-2025 | |
| Amgen INC. | $226.49 | 2024-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $206.60 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $149.03 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $145.55 | 2025 | Arexvy, Shingrix, Penmenvy |
| Astrazeneca Pharmaceuticals LP | $106.03 | 2024-2025 | Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $92.73 | 2025 | Caplyta |
| Abbott Laboratories | $81.58 | 2025 | Freestyle Libre |
| Abbvie INC. | $61.62 | 2024-2025 | |
| Viatris Specialty LLC | $43.53 | 2025 | Yupelri |
| Dexcom, INC. | $38.75 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $36.51 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $31.19 | 2024-2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $29.55 | 2024 | Austedo Xr |
| Phathom Pharmaceuticals, INC. | $25.49 | 2025 | Voquezna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $23.93 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $22.46 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $21.70 | 2025 | Auvelity |
| Antares Pharma, INC. | $20.56 | 2025 | Xyosted |
| Novartis Pharmaceuticals Corporation | $20.15 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.33 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.12 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Britny Rockelman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.